Margaret Shipp, MD, is Chief of the Division of Hematologic Neoplasia at Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School. Her research focuses on the clinical and molecular heterogeneity of the large B-cell lymphomas (LBCLs) and Hodgkin lymphomas. Dr. Shipp has led efforts to define molecular signatures of LBCLs and Hodgkin lymphomas, identify biologically distinct subsets of these diseases, and characterize associated rational treatment targets including modulators of the host anti-tumor immune response.

Margaret Shipp MD
Dana-Farber Cancer Institute
Boston, Massachusetts
United States
Project Title
Analysis and Targeting of Tumor-Associated Monocytes/Macrophages that Inhibit PD-1 Blockade
Program
Translational Research Program